ALN-2232: ALN-2232 will be administered subcutaneously (SC)
Placebo: Placebo will be administered SC
Tirzepatide: Tirzepatide will be administered SC
Study summary
The purpose of this study is to:
* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
All Parts:
* Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
* Has a hemoglobin A1c (HbA1c) \<6.5%
Exclusion Criteria:
All Parts:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies for chronic weight management or antidiabetic medications
Note: other protocol defined inclusion/exclusion criteria apply
Primary outcome measure(s)
Part A: Frequency of Adverse Events (AEs) — Up to 12 months
Part B: Percent Change from Baseline in Body Weight — Baseline up to Month 6
Part C: Percent Change from Baseline in Body Weight — Baseline up to Month 6
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
